This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's Diversified Dividend Portfolio

1. Eli Lilly (LLY - Get Report) (LLY): With a hefty 5.8% yield, the Indianapolis-based Lilly has one of the highest yields of any big pharma major pharmaceutical company, and it's the only member of that cohort still consistently raising its dividend. Pfizer (PFE) (PFE) cut its payout, while Wyeth (WYE), Merck (MRK) (MRK), and Bristol-Myers (BMY) are just holding pat. Lilly's willingness to raise increase its payout is sign of strength that you will find nowhere else in big pharma. The company made some smart acquisitions in 2008, including buying ImClone for $6 billion.

The ImClone acquisition was worth every penny. Its strong biotech franchise provides immediate growth, the kind that companies like Lilly salivate over, thanks to the cancer drug Erbitux. The acquisition also helps bolster Lilly's drug pipeline before its current top-seller, the anti-psychotic Zyprexa, stands to lose patent protection in 2011. Thanks to Erbitux, Lilly is now one of very few companies with a strong anti-cancer franchise, a category of drugs that governments around the world are still willing to reimburse insurers for. That matters at a time when almost every developed country faces ballooning budget deficits, and the President of the United States is committed to cutting healthcare costs.

How about that dividend? Eli Lilly has boosted its payout for 41 consecutive years, most recently in December 2008 when it raised its quarterly dividend to 49 cents a share, which comes to $1.96 annually. How does Lilly stand up to the safety test? The company can cover its payout 2.2 times with expected 2009 earnings of $4.22 a share. Two thumbs up, way up. And since Lilly's profit is expected to grow another 7% in 2010, we will likely see more dividend boosts here. Eli has a fair amount of debt on its balance sheet, but it still garners an A-rating from the major agencies. Part of this is because the company only has $400 million coming due in 2009, and nothing else until 2012. No need to worry on that front, either. But not everything is smooth sailing in this stock.

4 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
PGF $18.54 0.05%
ED $59.80 1.70%
KMP $102.03 1.98%
LLY $73.58 0.19%
T $32.75 -0.21%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs